Maternal nutrition companies are filing more patents around probiotics and human milk oligosaccharides. But the more important signal is what they are trying to protect. It is no longer enough to own or source a probiotic strain or HMO.

Companies are increasingly protecting specific combinations and linking them to outcomes such as maternal mental health, gut microbiome changes, infant immunity, pregnancy complications, and early development.

One finding stood out.

Patent activity in the reproductive health formulation cluster increased 136% from 2024 to 2026. Nestlé and Heilongjiang Feihe Dairy together accounted for 44 innovations within a 272-patent cluster. Their activity is concentrated around complex bioactive mechanisms rather than conventional vitamin formulations.

At the same time, much of the diagnostic research that could support personalized maternal nutrition sits outside these corporate portfolios. That separation creates one of the more interesting R&D opportunities in this field.

Where is Maternal Nutrition Patent Activity becoming Concentrated?

Nestlé and Feihe Dairy are concentrating their patent activity on specific bioactive combinations tied to defined maternal and infant health outcomes.

Nestlé’s work includes Lactococcus lactis and Bifidobacterium combinations for maternal anxiety and related health applications, while Feihe has focused on 2′-fucosyllactose (2′-FL) and its role in shaping maternal and infant gut microbiota. Other patents in the same cluster combine ingredients such as myo-inositol with probiotics to address outcomes including premature membrane rupture.

Together, these filings point to a broader change in maternal nutrition R&D. Companies are moving beyond products built mainly around correcting nutrient deficiencies and toward formulations designed around specific metabolic, microbial, and reproductive outcomes.

This also changes where IP differentiation is emerging. The value is increasingly in how an ingredient or strain is used, what it is combined with, and which health outcome the formulation is designed to address, rather than in the ingredient alone.

Why are HMO and probiotic combinations becoming strategically important?

HMOs and probiotics solve different parts of the microbiome equation.

Human milk oligosaccharides act primarily as substrates that can support selected microorganisms. Certain bifidobacterial strains are particularly well adapted to use specific HMOs.

Research has shown that maternal diet can alter HMO composition in breast milk and that these changes are associated with differences in the milk microbiome.

Earlier patent research also established that selected HMOs can preferentially support Bifidobacterium infantis, demonstrating why companies may want to protect the relationship between a particular oligosaccharide and a particular microorganism rather than either component alone.

For product developers, this changes the formulation question.

The question is no longer only which probiotic strain or HMO should be included.

It becomes which HMO, strain, dose, population, mechanism, and health outcome can be connected strongly enough to support differentiation and eventually a defensible claim. That creates a much higher evidence requirement.

Maternal nutrition IP is moving from nutrient levels to biological outcomes

The technical focus in maternal nutrition is moving beyond correcting deficiencies and toward influencing the microbiome, metabolism, and longer-term reproductive health outcomes.

China Medical University has filed around oleic acid for delaying ovarian aging, while Nestlé has explored isoflavone-based approaches for cognitive support during menopause. This widens the opportunity from pregnancy-specific nutrition to interventions that support women across different stages of reproductive health.

The way efficacy is measured is also becoming more complex. Traditional maternal supplements are often assessed through markers such as vitamin D or B12 levels. Newer approaches look at changes in gut microbiota, maternal anxiety, infant development, and other physiological outcomes. Other innovations, including compositions based on milk exosomes and colostrum basic protein, show how companies are exploring more targeted forms of nutritional intervention.

This creates a higher validation burden for R&D teams. Showing that a particular probiotic strain improves maternal anxiety, or that 2′-FL influences infant immune or microbiome outcomes, requires more extensive evidence than showing that a supplement raises a nutrient level. Studies may need to follow mothers and infants over longer periods while combining microbiome analysis with clinical or developmental measurements.

The challenge is whether that evidence can be generated quickly enough to support commercialization. If validation and regulatory pathways take too long, companies could spend a significant part of the patent term proving the value of the intervention. This makes the timing of clinical development increasingly important, especially for companies building IP around complex bioactive combinations rather than established nutrients.

Academic Diagnostics and Corporate Bioactives Are Evolving on Separate Tracks

Academic institutions such as Ahmadu Bello University and Jimma University are active across several diagnostic and monitoring areas rather than concentrating on complex bioactive formulations. Ahmadu Bello University appears across five clusters, while Jimma University contributed 14 innovations across three clusters covering areas such as serum analysis, anemia management, and menopausal monitoring. This is very different from the concentration seen among companies such as Nestlé and Feihe in the reproductive health formulation cluster.

The split is important because the groups developing diagnostic tools are not the same groups building advanced nutritional interventions. Academic research is contributing to areas such as biomarker analysis, MUAC validation, iodine status, and other monitoring approaches, while corporate portfolios are more focused on formulation, delivery, and bioactive combinations.

That creates a gap for personalized maternal nutrition. A product that adapts its formulation based on a woman’s nutritional status or biomarkers needs both sides to work together. It needs a reliable way to identify what the user needs, and it also needs a stable formulation that can deliver the right intervention.

Today, those capabilities often sit in separate IP portfolios. Academic institutions are stronger on diagnostic validation, while corporate players have more experience in formulation development and manufacturing. For companies trying to build personalized maternal nutrition products, this can increase complexity because the diagnostic layer and the intervention layer may need to be sourced, licensed, or developed separately.

A system that adjusts a probiotic, HMO, or other bioactive formulation using real-time biomarkers would therefore require much closer integration between these two areas. Until that happens, the separation between diagnostic research and commercial formulation remains both a development challenge and a potential opportunity.

High-Value Maternal Nutrition Claims Are Becoming Concentrated Around Specific Bioactive Combinations

Some of the most valuable maternal health outcomes are being tied to increasingly specific formulation strategies. Nestlé has patents around Lactococcus lactis and Bifidobacterium combinations for maternal anxiety, while Feihe has filed around 2′-FL and microbiome-related applications across mothers and infants. Other filings combine myo-inositol with probiotics for premature birth prevention and folic acid with fucoidan for offspring nervous system development.

What stands out is that these patents are not simply protecting an ingredient. They connect a particular bioactive or combination with a defined health outcome. That makes areas such as maternal anxiety, premature birth, microbiome modulation, and infant neurodevelopment more strategically important from an IP perspective.

This also creates a different competitive challenge for companies entering the space. Players such as By-health and Junlebao Dairy Group appear less active in these more complex formulation areas, which could make it harder for them to compete through similar claims without developing alternative combinations, building their own supporting IP, or relying on partnerships and licensing.

There may still be room around standalone HMOs, single-strain probiotics, and other less crowded applications, but the more protected areas are increasingly those that combine specific ingredients with defined maternal or infant outcomes. For R&D teams, that makes early patent mapping important before selecting strains, HMOs, or claim areas for development.

The strategic choice is therefore not simply whether to work with probiotics or HMOs. It is whether to compete in already crowded outcome areas or explore mechanisms that appear less occupied, such as maternal metabolic resilience or other microbiome-linked pathways outside the claims currently being pursued by major players.

The Biggest Whitespace May Be in Connecting Diagnostics With Maternal Nutrition Interventions

Diagnostic research is advancing in areas such as MUAC-based nutritional assessment, urinary iodine biomarkers, and other low-cost monitoring approaches. Institutions including the University of São Paulo, Tanzania Food and Nutrition Center, and the Indian Council of Medical Research are contributing to this work, but these diagnostic capabilities remain largely separate from commercial bioactive formulation strategies.

That separation creates an interesting opportunity for personalized maternal nutrition. Rather than offering the same formulation to every consumer, future products could use diagnostic inputs to adjust the type, dose, or timing of an intervention. For example, maternal nutritional status or biomarker data could help determine when a probiotic-HMO combination is appropriate or whether the composition should change for different physiological needs.

Low-cost and decentralized assessment methods could make this easier to implement outside traditional clinical settings. Measures such as MUAC and field-ready biomarkers can potentially support faster nutritional assessment without relying entirely on laboratory infrastructure, making personalized approaches more practical in a wider range of populations.

This is where the whitespace may be more attractive than developing another HMO or probiotic strain. Corporate IP is already becoming denser around specific bioactive formulations, while the connection between diagnostics and those interventions appears less developed. Building that link could allow companies to differentiate through how they identify the right intervention for the right user rather than competing only on the formulation itself.

For R&D teams, the opportunity is to investigate whether biomarkers such as maternal nutritional status, iodine levels, or other measurable indicators can reliably predict response to specific bioactive combinations. If that relationship can be validated, the diagnostic layer could become an important part of both personalization and future IP strategy.

The Next Competitive Advantage May Come From Connecting Bioactive IP With Diagnostics

The maternal nutrition landscape is developing along two separate tracks. Companies such as Nestlé and Feihe are building IP around bioactive formulations, while academic institutions are contributing more heavily to diagnostics, biomarkers, and nutritional assessment. What remains less developed is the connection between the two.

That gap could become strategically important. The value may not sit only with the company that owns a probiotic, HMO, or other bioactive formulation. It could also sit with the organization that can determine which intervention is most appropriate for a specific woman based on measurable physiological or nutritional signals.

Corporate players currently appear stronger in formulation and delivery, while academic institutions are more active in diagnostic validation. If those two areas begin to converge, personalized maternal nutrition could move from broad supplementation toward products selected or adjusted using biomarkers, nutritional status, or other diagnostic inputs.

For R&D teams, this changes the strategic question from simply deciding which formulation to develop. It also raises questions around whether to build diagnostic capabilities internally, license them from academic groups, or form partnerships that combine both sides of the value chain.

This is where Slate can help. By analyzing patents and research across multiple technology clusters, Slate can show where bioactive IP is becoming crowded, where diagnostic capabilities sit outside commercial portfolios, and where the two have not yet been connected.

For teams evaluating maternal nutrition opportunities, Slate can help identify which mechanisms are already well protected, which diagnostic approaches remain disconnected from commercial formulations, and where a build, license, or partnership strategy may make more sense before significant R&D investment is committed.

Frequently Asked Questions

What is the difference between HMOs and probiotics in maternal nutrition?

Human milk oligosaccharides, or HMOs, are complex carbohydrates found naturally in breast milk that can support beneficial gut bacteria. Probiotics are live microorganisms used to influence the gut microbiome. In maternal nutrition, the more interesting IP activity is increasingly around how specific HMOs, probiotic strains, and other bioactives are combined for defined maternal or infant health outcomes.

Why are Nestlé and Feihe important players in maternal nutrition IP?

In the Slate-analyzed reproductive health formulation cluster, Nestlé and Feihe show notable activity around complex bioactive formulations. Their patents cover areas such as probiotic combinations, 2′-FL, microbiome modulation, maternal health, and infant outcomes. This suggests that both companies are building portfolios around more specific mechanisms and applications rather than relying only on conventional nutrient formulations.

Can new entrants still compete in maternal nutrition?

Yes. The opportunity may be stronger in areas where existing patent activity is less concentrated. Companies can explore alternative strain combinations, different biological mechanisms, new target populations, or diagnostic-led personalization. Early patent mapping is important because it can show where a planned formulation overlaps existing claims and where there may still be room to differentiate.

What role do academic institutions play in maternal nutrition innovation?

Academic institutions such as Ahmadu Bello University and Jimma University appear more active in areas related to diagnostics, nutritional assessment, biomarkers, anemia, and monitoring. Their work is less concentrated in complex commercial bioactive formulations. This creates an important gap between diagnostic research and the formulation capabilities being developed by large nutrition companies.

What is MUAC and why does it matter for maternal nutrition?

Mid-Upper Arm Circumference, or MUAC, is a simple anthropometric measurement used to assess nutritional status. It can be useful in settings where more complex clinical measurements are difficult to access. For maternal nutrition, tools such as MUAC could eventually support more personalized interventions by helping identify which women may need different nutritional support.

Why is diagnostic integration important for personalized maternal nutrition?

Most current products are still designed around predefined formulations. Diagnostic integration could allow the type, dose, or timing of an intervention to change based on nutritional status, biomarkers, or other measurable signals. This could create a new layer of differentiation beyond the formulation itself.

What is the difference between ingredient-driven and mechanism-driven IP?

Ingredient-driven IP focuses mainly on protecting a compound, strain, or formulation component. Mechanism-driven IP connects that ingredient or combination with a defined biological pathway, population, or health outcome. In maternal nutrition, the shift toward specific probiotic combinations, HMOs, and outcome-linked formulations suggests that mechanism-driven IP is becoming increasingly important.